文献速递胸部肿瘤放疗放疗物理与技术

左侧肺癌放疗中心脏亚结构剂量量化与优化

Cardiac Substructure Dose Quantification and Optimization in Left-Sided Lung Cancer Radiotherapy.
PubMed 文献 · Pract Radiat Oncol · 2026-09-11

BACKGROUND: As curative-intent radiation therapy provides excellent local control for lung tumors, patients are surviving longer to experience treatment-associated adverse cardiac events.…

要点

  • 平均剂量最高为主动脉弓38.6Gy、肺动脉33.3Gy、肺静脉28.8Gy、左回旋支27.3Gy
  • 重新规划可显著降低左前降支V15Gy(83.8%→13.7%)

核心结论

  • 左侧肺癌放疗中多个心脏亚结构受照剂量超过全心阈值,战略性地重新规划可降低亚结构剂量,尤其左冠状动脉。

研究设计与样本

  • 机构数据集纳入2015-2025年50例左侧局部晚期原发性肺癌接受根治性光子放疗60Gy/30次的患者,基于对比增强CT手动勾画21个心脏亚结构。
  • 从治疗剂量体积直方图提取亚结构平均和最大剂量,分析其与靶区体积、肿瘤位置和人口学特征的关系。
  • 对15例全心平均剂量超过9Gy的病例进行战略性重新规划,评估亚结构剂量降低的可行性。

主要发现

  • 平均亚结构剂量与机构全心平均剂量约束10Gy比较,平均剂量最高的四个亚结构(含95%CI)为:主动脉弓38.6 [32.7-43.8] Gy、肺动脉33.3 [29.4-36.8] Gy、肺静脉28.8 [24.9-32.4] Gy、左回旋支冠状动脉27.3 [21.8-32.7] Gy。
  • 全队列平均左前降支V15Gy为52.7%,在高全心剂量队列中达83.8%。
  • 重新规划后左前降支V15Gy降至13.7%。

关键数值与推荐

  • 机构全心平均剂量约束为10Gy。
  • 高全心剂量队列定义:全心平均剂量超过9Gy。

临床怎么用

  • 左侧肺癌放疗时应考虑勾画和约束心脏亚结构,而非仅关注全心剂量。
  • 对全心平均剂量接近或超过9Gy的病例,可尝试重新规划以降低亚结构剂量,尤其左前降支。
  • 本研究提供的勾画和剂量数据集可用于预测建模和亚结构保护策略开发。

局限性

  • 单机构回顾性研究,样本量50例。
  • 手动勾画21个心脏亚结构,可能受勾画者间差异影响。
  • 重新规划仅针对15例全心平均剂量>9Gy的病例,可行性结论限于该亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: As curative-intent radiation therapy provides excellent local control for lung tumors, patients are surviving longer to experience treatment-associated adverse cardiac events. Patients treated for left-lung tumors are particularly vulnerable due to the heart's anatomical proximity. While the whole heart is conventionally contoured as an organ-at-risk, emerging research highlights cardiac substructure doses better predict cardiotoxicity post-radiotherapy than mean heart dose. METHODS: An institutional dataset of 50 contrast-enhanced CT scans was compiled from patients treated between 2015 and 2025 for left-sided locally advanced primary lung cancers with definitive photon radiotherapy to 60 Gy in 30 fractions. Twenty-one cardiac substructures were manually contoured on each CT per gold-standard atlases and novel protocols. Mean and maximum substructure doses were extracted from treatment dose-volume histograms, and associations between substructure dose, target volume, tumor location, and demographics were analyzed. Strategic treatment replanning of the 15 cases exceeding a mean whole heart dose of 9 Gy evaluated feasibility of substructure dose reduction. RESULTS: Mean substructure radiation doses were compared against the optimal institutional whole-heart mean dose constraint of 10 Gy. The four highest average mean dose results with 95% confidence intervals were: Aortic Arch 38.6 [32.7-43.8] Gy, Pulmonary Artery 33.3 [29.4-36.8] Gy, Pulmonary Veins 28.8 [24.9-32.4] Gy, and Left Circumflex Coronary Artery 27.3 [21.8-32.7] Gy. In the full cohort, average LAD V15 Gy was 52.7%; in the elevated heart dose cohort, it reached 83.8%. Following replanning, LAD V15 Gy was reduced to 13.7%. CONCLUSION: This is one of few quantifications of substructure dosimetry in left-sided lung radiotherapy. Eleven substructures received mean doses exceeding the institutional whole-heart threshold, underscoring the need to consider substructures treatment planning. Strategic replanning demonstrates clinical feasibility in reducing substructure doses, particularly the left-sided coronary arteries. The resulting contour and dose datasets provide a foundation for predictive modeling and substructure-sparing treatment strategies.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Wildman VL, Qiu RLJ, Luca K, et al. Cardiac Substructure Dose Quantification and Optimization in Left-Sided Lung Cancer Radiotherapy. Pract Radiat Oncol. 2026. PMID: 42727773. doi:10.1016/j.prro.2026.08.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。